Skip to main content
Ocumension Therapeutics logo

Ocumension Therapeutics — Investor Relations & Filings

Ticker · 1477 ISIN · KYG674111011 LEI · 5493000USURI3SIL4Z85 HKEX Manufacturing
Open in API
Filings indexed 460 across all filing types
Latest filing 2021-04-07 Regulatory Filings
Country KY Cayman Islands
Listing HKEX 1477

About Ocumension Therapeutics

http://www.ocumension.com

Ocumension Therapeutics is an ophthalmic pharmaceutical platform company dedicated to the research, development, and commercialization of first-in-class or best-in-class therapeutics. The company focuses on providing comprehensive treatment solutions for Chinese patients suffering from ocular diseases. Ocumension has established a complete ophthalmic drug product line, currently holding 20 drug assets covering both anterior and posterior segments of the eye. Its portfolio addresses major conditions such as chronic non-infectious uveitis, infective and allergic conjunctivitis, and diabetic macular edema. The company employs a strategy combining continuous scientific innovation, independent R&D, and strategic alliances to sustain the supply of innovative products across the ophthalmology field.

Recent filings

Filing Released Lang Actions
VOLUNTARY ANNOUNCEMENT FIRST PATIENT ENROLLED IN THE PHASE III CLINICAL TRIAL OF OT-101 IN THE UNITED STATES AND THE PLANNED REAL WORLD STUDY FOR OT-101 IN CHINA
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by Ocumension Therapeutics regarding the enrollment of the first patient in a Phase III clinical trial and plans for a real world study. It is a business update about clinical development progress, not a financial report, regulatory filing, or meeting material. The document is relatively short (3295 characters) and does not contain financial data, audit information, or voting results. It is an announcement of a business development event, which fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2021-04-07 English
VOLUNTARY ANNOUNCEMENT NEW DRUG APPLICATION FOR OT-401 ACCEPTED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by Ocumension Therapeutics regarding the acceptance of a new drug application (NDA) for OT-401 by the National Medical Products Administration (NMPA) in China. It provides business updates about the company's drug development progress and regulatory acceptance. The document is relatively short (3248 characters) and does not contain financial statements, detailed financial data, or comprehensive report content. It is an announcement informing shareholders and investors about a regulatory milestone rather than a full report or detailed financial disclosure. There is no indication that this is a regulatory filing for compliance or certification, nor is it a report publication announcement stating that a report is attached or available elsewhere. The content fits best under a general regulatory or business update announcement category. Given the available categories, the best fit is Regulatory Filings (RNS), which serves as a fallback for miscellaneous regulatory or business announcements that do not fit other specific categories.
2021-04-07 English
ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2020
Annual Report Classification · 95% confidence The document is titled 'ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2020' and contains detailed audited consolidated annual results, financial highlights, business review, and management discussion and analysis for the full fiscal year ending December 31, 2020. It includes comprehensive financial data, business performance, R&D milestones, and other substantive information typical of a full annual report. The document is about 15,000 characters long, indicating it is a full report rather than a brief announcement or summary. It is not a mere announcement of report publication or a certification letter. Therefore, the document fits the definition of an Annual Report (10-K). FY 2020
2021-03-19 English
List of Directors and their Role and Function
Board/Management Information Classification · 95% confidence The document lists the members of the board of directors and their roles, including committee memberships. It does not contain financial data, audit results, or meeting minutes. It is an announcement related to the company's board structure and management roles. Therefore, it fits the category of Board/Management Information (MANG). The document length is short and focused solely on board composition, confirming it is not a full report or other filing type.
2021-03-19 English
CHANGE OF NON-EXECUTIVE DIRECTOR
Board/Management Information Classification · 100% confidence The document is an announcement from Ocumension Therapeutics regarding the resignation of a non-executive director and the appointment of a new non-executive director. It details the changes in the board composition, including biographical information about the new appointee and confirms no disagreements or other issues related to the resignation. There is no financial data, no mention of a report or financial results, and the content focuses solely on board/management changes. Therefore, this fits the category of Board/Management Information (MANG). The document length is 4186 characters, which is consistent with a typical announcement of this nature rather than a full report or regulatory filing.
2021-03-19 English
VOLUNTARY ANNOUNCEMENT INCLUSION OF THE SHARES OF THE COMPANY IN THE HONG KONG STOCK CONNECT LIST UNDER THE SHENZHEN-HONG KONG STOCK CONNECT
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by Ocumension Therapeutics regarding the inclusion of its shares in the Hong Kong Stock Connect list under the Shenzhen-Hong Kong Stock Connect. It is an announcement about a change in the company's stock listing status and trading accessibility, not a financial report, management change, or voting result. The document is relatively short (2568 characters) and serves as a public notice of this inclusion event. This fits best under a general regulatory announcement category rather than a detailed financial or management report. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2021-03-15 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.